Osteoporosis is one of the most common metabolic skeletal diseases, which affects more than 200 million people worldwide, especially elderly and postmenopausal women. One of the main processes of osteoporosis is attenuated bone formation. Abundant evidence has confirmed that overactivated osteoclasts are responsible for the attenuated bone formation. This study aims at identifying novel methylation-associated biomarkers and therapeutic targets in osteoclasts by integrally analyzing methylation profiles and gene expression data. DNA methylation profile and gene expression data were obtained from the Gene Expression Omnibus (GEO) database. Subsequently, we integrated the two sets of data to screen for differentially expressed genes with differential methylation level (DM-DEGs) between osteoclasts and CD14+ monocytes from donors. Then, Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed to uncover the enriched functions and pathways of identified DM-DEGs. In addition, by combining protein-protein interaction analysis and receiver-operator characteristic analysis, we finally identified four hub DM-DEGs. Gene Set Enrichment Analysis was utilized to validate and investigate the potential biological functions of the four hub DM-DEGs. Finally, Real-time quantitative PCR (QPCR) was performed to validate the mRNA expression level of the four identified hub DM-DEGs during osteoclast differentiation. CCRL2, CCL18, C1QB, and SELL were highly correlated with osteoclastic differentiation and osteoporosis phenotype. QPCR revealed that the expression of CCRL2, CCL18, and C1QB was increased during osteoclast differentiation, whereas the expression of SELL was decreased. The present study indicated a connection between gene expression and DNA methylation during osteoclast differentiation and that four hub DM-DEGs in osteoclastogenesis and osteoporosis pathogenesis might be potential candidates for intensive research and therapeutic targets for the treatment of osteoporosis.
Get full access to this article
View all access options for this article.
References
1.
ArmbrustT., NordmannB., KreissigM., and RamadoriG. (1997). C1Q synthesis by tissue mononuclear phagocytes from normal and from damaged rat liver: up-regulation by dexamethasone, down-regulation by interferon gamma, and lipopolysaccharide. Hepatology, 26, 98–106.
2.
AsagiriM., and TakayanagiH. (2007). The molecular understanding of osteoclast differentiation. Bone, 40, 251–264.
3.
AstlefordK., CampbellE., NortonA., and ManskyK.C. (2020). Epigenetic regulators involved in osteoclast differentiation. Int J Mol Sci 21,7080.
4.
AwasthiH., ManiD., SinghD., and GuptaA. (2018). The underlying pathophysiology and therapeutic approaches for osteoporosis. Med Res Rev, 38, 2024–2057.
5.
BandettiniW.P., KellmanP., ManciniC., BookerO.J., VasuS., LeungS.W., WilsonJ.R., et al. (2012). MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson 11,83.
6.
BellinghausenI., ReuterS., MartinH., MaxeinerJ., LuxemburgerU., TureciO., et al. (2012). Enhanced production of CCL18 by tolerogenic dendritic cells is associated with inhibition of allergic airway reactivity. J Allergy Clin Immunol, 130, 1384–1393.
7.
BendtzenK. (2015). Immunogenicity of Anti-TNF-alpha Biotherapies: I. individualized medicine based on immunopharmacological evidence. Front Immunol 6,152.
8.
BoissyP., LenhardT.R., KirkegaardT., PeschonJ.J., BlackR.A., DelaisséJ.-M., et al. (2003). An assessment of ADAMs in bone cells: absence of TACE activity prevents osteoclast recruitment and the formation of the marrow cavity in developing long bones. FEBS Lett, 553, 257–261.
9.
BondueB., WittamerV., and ParmentierM. (2011). Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev, 22, 331–338.
10.
BoyleW.J., SimonetW.S., and LaceyD.L. (2003). Osteoclast differentiation and activation. Nature, 423, 337–342.
11.
BruserudO., and KittangA.O. (2010). The chemokine system in experimental and clinical hematology. Curr Top Microbiol Immunol, 341, 3–12.
12.
ChellaiahM.A. (2005). Regulation of actin ring formation by rho GTPases in osteoclasts. J Biol Chem, 280, 32930–32943.
13.
ChenZ., LiuB., YiM., QiuH., and YuanX. (2020). A prognostic nomogram model based on mRNA expression of DNA methylation-driven genes for gastric cancer. Front Oncol 10,584733.
14.
ChinC.H., ChenS.H., WuH.H., HoC.W., KoM.T., and LinC.Y. (2014). cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8 Suppl 4,S11.
15.
CloughE., and BarrettT. (2016). The Gene Expression Omnibus Database. Methods Mol Biol, 1418, 93–110.
16.
ClowesJ.A., RiggsB.L., and KhoslaS. (2005). The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev, 208, 207–227.
17.
Del PreteA., Martinez-MunozL., MazzonC., ToffaliL., SozioF., ZaL., et al. (2017). The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage. Blood, 130, 1223–1234.
18.
Delgado-CalleJ., SañudoC., FernándezA.F., García-RenedoR., FragaM.F., and RianchoJ.A. (2014). Role of DNA methylation in the regulation of the RANKL-OPG system in human bone. Epigenetics, 7, 83–91.
19.
DongY., PengR., KangH., SongK., GuoQ., ZhaoH., et al. (2021). Global incidence, prevalence, and disability of vertebral fractures: a systematic analysis of the global burden of disease study 2019. Spine J [Epub ahead of print]; DOI: 10.1016/J.SPINEE.2021.12.007.
20.
FanP., KyawH., SuK., ZengZ., AugustusM., CarterK.C., et al. (1998). Cloning and characterization of a novel human chemokine receptor. Biochem Biophys Res Commun, 243, 264–268.
21.
FeinbergA.P. (2008). Epigenetics at the Epicenter of Modern Medicine. JAMA, 299, 1345–1350.
22.
FouquetH., GiovannelliJ., de NadaiP., BalsamelliJ., BergerP., BourdinA., et al. (2020). Is CCL18 a potential biomarker of type-2 asthma endotypes?. J Asthma, 59, 536–540.
23.
FrisoS., PizzoloF., ChoiS.W., GuariniP., CastagnaA., RavagnaniV., et al. (2008). Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis, 199, 323–327.
24.
Garcia-GomezA., LiT., KerickM., Catala-MollF., CometN.R., Rodriguez-UbrevaJ., et al. (2017). TET2- and TDG-mediated changes are required for the acquisition of distinct histone modifications in divergent terminal differentiation of myeloid cells. Nucleic Acids Res, 45, 10002–10017.
25.
GennariL., MerlottiD., FalchettiA., Eller VainicherC., CossoR., and ChiodiniI. (2020). Emerging therapeutic targets for osteoporosis. Expert Opin Ther Targets, 24, 115–130.
26.
GennariL., RotatoriS., BianciardiS., GonnelliS., NutiR., and MerlottiD. (2015). Appropriate models for novel osteoporosis drug discovery and future perspectives. Expert Opin Drug Discov, 10, 1201–1216.
27.
GuoJ., RenR., SunK., HeJ., and ShaoJ. (2021). PERK signaling pathway in bone metabolism: friend or foe?. Cell Proliferation 54,e13011.
28.
GuoY.C., ZhangS.W., and YuanQ. (2018). Deubiquitinating enzymes and bone remodeling. Stem Cells Int 2018,3712083.
29.
HeJ., LiJ.C., XieH., XuZ.H., SunY.W., and ShanQ. (2015). Serum chemerin levels in relation to osteoporosis and bone mineral density: a case-control study. Dis Markers 2015,786708.
30.
HolersV.M., and BandaN.K. (2018). Complement in the initiation and evolution of rheumatoid arthritis. Front Immunol 9,1057.
31.
HsiaoH.B., LinH., WuJ.B., and LinW.C. (2013). Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-kappaB pathways. Osteoporos Int, 24, 1663–1676.
32.
HsuY.L., HungJ.Y., KoY.C., HungC.H., HuangM.S., and KuoP.L. (2010). Phospholipase D signaling pathway is involved in lung cancer-derived IL-8 increased osteoclastogenesis. Carcinogenesis, 31, 587–596.
33.
HuK., JiangW., SunH., LiZ., RongG., and YinZ. (2019). Long noncoding RNA ZBED3-AS1 induces the differentiation of mesenchymal stem cells and enhances bone regeneration by repressing IL-1beta via Wnt/beta-catenin signaling pathway. J Cell Physiol, 234, 17863–17875.
34.
IgnatiusA., SchoengrafP., KrejaL., LiedertA., RecknagelS., KandertS., et al. (2011). Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β. J Cell Biochem, 112, 2594–2605.
35.
IveticA. (2018). A head-to-tail view of L-selectin and its impact on neutrophil behaviour. Cell Tissue Res, 371, 437–453.
36.
IveticA., Hoskins GreenH.L., and HartS.J. (2019). L-selectin: A Major Regulator of Leukocyte Adhesion, Migration and Signaling. Front Immunol 10,1068.
37.
JonesP.A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet, 13, 484–492.
38.
KhanU.A., HashimiS.M., BakrM.M., ForwoodM.R., and MorrisonN.A. (2016). CCL2 and CCR2 are essential for the formation of osteoclasts and foreign body giant cells. J Cell Biochem, 117, 382–389.
39.
KimJ.H., and KimN. (2014). Regulation of NFATc1 in osteoclast differentiation. J Bone Metab, 21, 233–241.
40.
KorbeckiJ., OlbromskiM., and DziegielP. (2020). CCL18 in the progression of cancer. Int J Mol Sci 21,7955.
41.
LengQ., ChenL., and LvY. (2020). RNA-based scaffolds for bone regeneration: application and mechanisms of mRNA, miRNA and siRNA. Theranostics, 10, 3190–3205.
42.
LewieckiE.M. (2011). New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol, 7, 631–638.
43.
LiE., and ZhangY. (2014). DNA methylation in mammals. Cold Spring Harb Perspect Biol 6,a019133.
44.
LiJ., YangS., LiX., LiuD., WangZ., GuoJ., et al. (2017). Role of endoplasmic reticulum stress in disuse osteoporosis. Bone, 97, 2–14.
45.
LiJ., ZhangT., HuangC., XuM., XieW., PeiQ., et al. (2021). Chemerin located in bone marrow promotes osteogenic differentiation and bone formation via Akt/Gsk3β/β-catenin axis in mice. J Cell Physiol, 236, 6042–6054.
46.
LiY., WangL., ZhangM., HuangK., YaoZ., RaoP., et al. (2020). Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt/beta-catenin signalling pathway via DNA methylation. Cell Prolif 53,e12834.
47.
LuoC., HajkovaP., and EckerJ.R. (2018). Dynamic DNA methylation: in the right place at the right time. Science, 361, 1336–1340.
48.
MassaroA.N., BammlerT.K., MacDonaldJ.W., PerezK.M., ComstockB., and JuulS.E. (2021). Whole genome methylation and transcriptome analyses to identify risk for cerebral palsy (CP) in extremely low gestational age neonates (ELGAN). Sci Rep 11,5305.
49.
McMichaelB.K., WysolmerskiR.B., and LeeB.S. (2009). Regulated proteolysis of nonmuscle myosin IIA stimulates osteoclast fusion. J Biol Chem, 284, 12266–12275.
50.
ModingerY., LofflerB., Huber-LangM., and IgnatiusA. (2018). Complement involvement in bone homeostasis and bone disorders. Semin Immunol, 37, 53–65.
MukaT., KoromaniF., PortillaE., O'ConnorA., BramerW.M., TroupJ., et al. (2016). The role of epigenetic modifications in cardiovascular disease: a systematic review. Int J Cardiol, 212, 174–183.
MuruganandanS., RomanA.A., and SinalC.J. (2010). Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res, 25, 222–234.
55.
NemetzA., TothM., Garcia-GonzalezM.A., ZagoniT., FeherJ., PenaA.S., et al. (2001). Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut, 49, 644–649.
56.
NguyenM.K., JeonO., DangP.N., HuynhC.T., VarghaiD., RiaziH., et al. (2018). RNA interfering molecule delivery from in situ forming biodegradable hydrogels for enhancement of bone formation in rat calvarial bone defects. Acta Biomater, 75, 105–114.
57.
Nikolac PerkovicM., Videtic PaskaA., KonjevodM., KouterK., Svob StracD., Nedic ErjavecG., et al. (2021). Epigenetics of Alzheimer's Disease. Biomolecules 11,195.
58.
Park-MinK.H. (2019). Metabolic reprogramming in osteoclasts. Semin Immunopathol, 41, 565–572.
59.
PuY., ChenX., ChenY., ZhangL., ChenJ., ZhangY., et al. (2021). Transcriptome and differential methylation integration analysis identified important differential methylation annotation genes and functional epigenetic modules related to vitiligo. Front Immunol 12,587440.
60.
RachnerT.D., KhoslaS., and HofbauerL.C. (2011). Osteoporosis: now and the future. Lancet, 377, 1276–1287.
61.
RaiszL.G. (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest, 115, 3318–3325.
62.
RajeM.M., and AshmaR. (2019). Epigenetic regulation of BMP2 gene in osteoporosis: a DNA methylation study. Mol Biol Rep, 46, 1667–1674.
63.
Ramos-JuniorE.S., LeiteG.A., Carmo-SilvaC.C., TairaT.M., NevesK.B., ColonD.F., et al. (2017). Adipokine Chemerin Bridges Metabolic Dyslipidemia and Alveolar Bone Loss in Mice. J Bone Miner Res, 32, 974–984.
64.
Rica., L.d.l., Rodríguez-Ubreva., J., and GarcíaM. (2013). PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation. Genome Biol 14,R99.
65.
RitchieM.E., PhipsonB., WuD., HuY., LawC.W., ShiW., et al. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43,e47.
66.
RzeniewiczK., NeweA., Rey GallardoA., DaviesJ., HoltM.R., PatelA., et al. (2015). L-selectin shedding is activated specifically within transmigrating pseudopods of monocytes to regulate cell polarity in vitro. Proc Natl Acad Sci U S A, 112, E1461–E1470.
67.
SaxenaY., RouthS., and MukhopadhayaA. (2021). Immunoporosis: role of Innate immune cells in osteoporosis. Front Immunol 12,687037.
68.
SchraufstatterI.U., DiscipioR.G., ZhaoM., and KhaldoyanidiS.K. (2009). C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol, 182, 3827–3836.
69.
SchutyserE., RichmondA., and Van DammeJ. (2005). Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol, 78, 14–26.
70.
SealesE.C., MicoliK.J., and McDonaldJ.M. (2006). Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. J Cell Biochem, 97, 45–55.
71.
SevereN., DieudonneF.X., and MarieP.J. (2013). E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis 4,e463.
72.
SuzukiK., ZhuB., RittlingS.R., DenhardtD.T., GoldbergH.A., McCullochC.A., et al. (2002). Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res, 17, 1486–1497.
73.
TakayamaK., SuzukiA., ManakaT., TaguchiS., HashimotoY., ImaiY., et al. (2009). RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro. J Bone Miner Metab, 27, 402–411.
74.
TelenM.J. (2014). Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors. Hematol Oncol Clin North Am, 28, 341–354.
75.
TeoB.H., BobryshevY.V., TehB.K., WongS.H., and LuJ. (2012). Complement C1q production by osteoclasts and its regulation of osteoclast development. Biochem J, 447, 229–237.
76.
TroyanskayaO., CantorM., SherlockG., BrownP., HastieT., TibshiraniR., BotsteinD., et al. (2001). Missing value estimation methods for DNA microarrays. Bioinformatics, 17, 520–525.
77.
TuZ., BuH., DennisJ.E., and LinF. (2010). Efficient osteoclast differentiation requires local complement activation. Blood, 116, 4456–4463.
78.
TwiskF. (2013). Rebuttal to Ickmans et al. association between cognitive performance, physical fitness, and physical activity level in women with chronic fatigue syndrome. J Rehabil Res Dev, 50, 795–810.
79.
WadaT., NakashimaT., HiroshiN., and PenningerJ.M. (2006). RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med, 12, 17–25.
80.
WalshM.C., TakegaharaN., KimH., and ChoiY. (2018). Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity. Nat Rev Rheumatol, 14, 146–156.
81.
WangK., ChenY., GaoS., WangM., GeM., YangQ., et al. (2021). Norlichexanthone purified from plant endophyte prevents postmenopausal osteoporosis by targeting ER alpha to inhibit RANKL signaling. Acta Pharm Sin B, 11, 442–455.
82.
WangX., LiuJ., WangD., FengM., and WuX. (2020). Epigenetically regulated gene expression profiles reveal four molecular subtypes with prognostic and therapeutic implications in colorectal cancer. Brief Bioinform 22,bbaa309.
83.
XuF., LiW., YangX., NaL., ChenL., and LiuG. (2020). The roles of epigenetics regulation in bone metabolism and osteoporosis. Front Cell Dev Biol 8,619301.
84.
XuF., and TeitelbaumS.L. (2013). Osteoclasts: new insights. Bone Res, 1, 11–26.
85.
YanagiharaY., InoueK., SaekiN., SawadaY., YoshidaS., LeeJ., et al. (2019). Zscan10 suppresses osteoclast differentiation by regulating expression of Haptoglobin. Bone, 122, 93–100.
86.
YaoL., YinH., HongM., WangY., YuT., TengY., et al. (2021). RNA methylation in hematological malignancies and its interactions with other epigenetic modifications. Leukemia, 35, 1243–1257.
87.
YoshimuraT., and OppenheimJ.J. (2008). Chemerin reveals its chimeric nature. J Exp Med, 205, 2187–2190.
88.
YuG., WangL.G., HanY., and HeQ.Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS, 16, 284–287.
89.
YuX., HuangY., Collin-OsdobyP., and OsdobyP. (2004). CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res, 19, 2065–2077.
90.
ZhangW., ChenL., WuJ., LiJ., ZhangX., XiangY., et al. (2019). Long noncoding RNA TUG1 inhibits osteogenesis of bone marrow mesenchymal stem cells via Smad5 after irradiation. Theranostics, 9, 2198–2208.
91.
ZhouJ., FujiwaraT., YeS., LiX., and ZhaoH. (2015). Ubiquitin E3 Ligase LNX2 is Critical for Osteoclastogenesis In Vitro by Regulating M-CSF/RANKL Signaling and Notch2. Calcif Tissue Int, 96, 465–475.
92.
ZhouY., GaoY., XuC., ShenH., TianQ., and DengH.W. (2018). A novel approach for correction of crosstalk effects in pathway analysis and its application in osteoporosis research. Sci Rep 8,668.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
